Media coverage about WAVE Life Sciences (NASDAQ:WVE) has been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. WAVE Life Sciences earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.2584433683596 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

WAVE Life Sciences (NASDAQ:WVE) opened at $39.35 on Friday. The company has a quick ratio of 11.50, a current ratio of 11.50 and a debt-to-equity ratio of 0.01. WAVE Life Sciences has a 52-week low of $15.15 and a 52-week high of $39.50.

WAVE Life Sciences (NASDAQ:WVE) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($0.94) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.97) by $0.03. The business had revenue of $0.68 million for the quarter, compared to analysts’ expectations of $0.77 million. WAVE Life Sciences had a negative return on equity of 59.52% and a negative net margin of 3,338.68%. analysts anticipate that WAVE Life Sciences will post -3.76 earnings per share for the current year.

WVE has been the topic of several analyst reports. Mizuho set a $34.00 target price on WAVE Life Sciences and gave the company a “buy” rating in a research report on Friday, August 18th. Jefferies Group reiterated a “buy” rating and set a $40.00 target price (down from $42.00) on shares of WAVE Life Sciences in a research report on Thursday, August 10th. Zacks Investment Research upgraded WAVE Life Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, October 12th. BidaskClub upgraded WAVE Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, August 26th. Finally, Leerink Swann reiterated an “outperform” rating and set a $53.00 target price (up from $42.00) on shares of WAVE Life Sciences in a research report on Wednesday, November 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $41.60.

In other WAVE Life Sciences news, Director Ra Capital Management, Llc purchased 423,398 shares of the firm’s stock in a transaction on Tuesday, November 14th. The shares were acquired at an average cost of $23.34 per share, with a total value of $9,882,109.32. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Chandra Vargeese sold 1,500 shares of the firm’s stock in a transaction dated Wednesday, November 22nd. The shares were sold at an average price of $35.00, for a total value of $52,500.00. The disclosure for this sale can be found here. 53.00% of the stock is owned by company insiders.

TRADEMARK VIOLATION WARNING: “WAVE Life Sciences (WVE) Getting Somewhat Favorable Media Coverage, Accern Reports” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/03/wave-life-sciences-wve-getting-somewhat-favorable-media-coverage-accern-reports.html.

About WAVE Life Sciences

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Insider Buying and Selling by Quarter for WAVE Life Sciences (NASDAQ:WVE)

Receive News & Stock Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related stocks with our FREE daily email newsletter.